Triglyceride clearance (None (no standard abbreviation for triglyceride clearance as a target))

Triglyceride clearance refers to the physiological process by which circulating triglycerides—primarily carried in chylomicrons and very low-density lipoproteins (VLDLs)—are removed from the bloodstream. This involves two main steps: 1. Hydrolysis by Lipases: Triglycerides within these particles are hydrolyzed by enzymes such as lipoprotein lipase (LPL) at capillary beds in muscle and adipose tissue, releasing free fatty acids for energy use or storage. This step is regulated by several apolipoproteins including apoCII (activator) and apoCIII/ANGPTLs (inhibitors)[4]. 2. Hepatic Clearance of Remnants: After most triglycerides have been removed from chylomicrons/VLDLs, the resulting remnant particles are taken up primarily by the liver through specific receptors including LDL receptor family members and heparan sulfate proteoglycans on hepatocytes[7][8]. Brown adipose tissue also plays an important role in accelerating plasma TG removal under certain conditions like cold exposure due to high local LPL activity mediated partly through CD36 receptors[3]. Impaired efficiency at any step leads to elevated plasma TGs—a major cardiovascular risk factor—and can result from genetic mutations affecting key proteins involved in this pathway. Because "triglyceride clearance" encompasses multiple molecules/processes rather than being itself a single therapeutic targetable entity, it should not be considered a canonical drug target but rather describes an important metabolic endpoint influenced by several potential targets within its regulatory network.[1][2][3][4]

Other names

Triglyceride metabolismPlasma triglyceride removalClearance of triglyceride-rich lipoproteins (TRLs)Lipid clearance

Activation/inhibition of lipoprotein lipase activity to enhance hydrolysis/removal of circulating TGs from TRLs/chylomicrons/VLDL particles. Modulation of apolipoprotein function—ApoCII activates LPL; ApoCIII inhibits it. Inhibition of ANGPTLs increases LPL activity. Enhancement/reduction in hepatic uptake/removal via LDL receptor or other endocytic receptors.